NASDAQ$TSHA

Taysha Gene Therapies Inc · Q4 2025 earnings

Q4 2025 earnings · · Before market open · Investor relations

Reports awaiting report

Taysha Gene Therapies hasn't published Q4 2025 actuals yet. The tiles below frame what to compare against; sections further down are historical context only.

  • Most recent report

    Q1 2026

    Revenue
    $0.00
    EPS
    -$0.12
  • Year-ago · Q4 2024

    Q4 2024

    Revenue
    $8.33M
    EPS
    -$0.36
  • FY2025 consensus

    Analyst consensus

    Revenue
    $4.83M
    EPS
    -$0.38

Revenue & EPS history

Taysha Gene Therapies · Revenue · Quarterly

$0

Q1 2026-100%vs Q1 2025
Beat estimate in 8 of 11 quarters(73%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2025

Historical avgQ4 2025

+10.9%

Avg return

Earnings day

+11.7%

Avg return

5 days after

+18.2%

Avg return

30 days after

52%

12 / 23 earnings

Positive

+195.0%

Q2 2023

Best reaction

-16.0%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-3.5%-6.3%
Q1 2026+0.6%-1.6%-20.9%
Q3 2025-5.9%-8.9%+18.3%
Q2 2025+5.4%+6.5%+17.4%
Q1 2025+8.1%+23.6%+7.2%
Q4 2024-4.7%-4.7%+13.5%
Q3 2024-5.0%-4.6%-13.4%
Q2 2024+9.1%+7.7%+11.0%
Q1 2024+29.6%+28.7%+73.7%
Q4 2023+39.0%+52.6%+13.1%
Q3 2023+26.3%+27.8%+16.5%
Q2 2023+195.0%+159.8%+312.7%
Q1 2023-10.5%-7.7%+14.7%
Q4 2022-6.5%+14.8%-3.9%
Q3 2022-5.5%+9.0%+2.5%
Q2 2022-16.0%-16.4%-29.9%
Q1 2022-4.1%-19.5%-12.5%
Q4 2021+3.1%+8.5%-40.5%
Q3 2021+0.2%-3.1%-9.3%
Q2 2021+0.7%-2.6%+20.1%
Q1 2021-0.7%+2.0%+19.9%
Q4 2020-7.2%-0.2%-19.9%
Q3 2020+2.2%+4.0%+10.3%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro